Global Olanzapine Market is valued at approximately USD 1.84 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 2.3% during the forecast period 2023-2030. Olanzapine is a medication used to treat certain mental health conditions, primarily schizophrenia and bipolar disorder. It belongs to a class of drugs called atypical antipsychotics. Olanzapine works by affecting the levels of certain neurotransmitters in the brain, such as dopamine and serotonin. These chemicals play a role in regulating mood, thoughts, and behavior. The Olanzapine Market is expanding because of factors such as the rising prevalence of schizophrenia in various regions, the surge in government initiatives to provide facilities for mental disorders and increasing consumer awareness regarding various mental disorders.

The Olanzapine Market is growing due to an increase in the frequency of neurological illnesses and a greater demand for the treatment of acute mania in bipolar disorders. Diseases such as schizophrenia are on the rise as the world's population grows at a pace of more than 1% per year, and people aren't receiving enough neutrinos. The prevalence of emotional and mental illnesses is rising as a result of changing lifestyles and increased job and life stress, which is expected to drive lucrative growth in the Olanzapine Market. According to the National Institute of Mental Health (NIH), 52.9 million adults in the United States experienced mental illness in 2020. As a result, an increase in the number of people suffering from mental illnesses that necessitate the use of olanzapine medicine to treat the condition drives market growth. Furthermore, according to World Health Organization (WHO) data in 2022, 1 out of every 8 individuals worldwide suffers from a mental condition. Additionally, in several regions, initiatives to expand investment in new Olanzapine medications are intensifying. This initiative tends to open up new development opportunities for the Olanzapine Market. However, the high cost of olanzapine and its adverse effects hampers the expansion of the Olanzapine Market throughout the forecast period of 2023-2030.

The key regions considered for the Global Olanzapine Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the factors such as the rising prevalence of mental diseases such as schizophrenia in the region, high insurance penetration and medical facilities, geographical expansion of key players in the region and favorable regulatory requirements. Asia Pacific is expected to grow significantly over the forecast period. This is attributed to increased government efforts to encourage a healthy lifestyle. Furthermore, the increasing number of medication stores and retail pharmacies selling olanzapine pharmaceuticals in the region contributes to market growth.

Major market player included in this report are:
Bristol-Myers Squibb Company
Dr. Reddy's Laboratories Ltd
Endo International plc
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Mylan N.V.
Novartis AG
Lupin Ltd.
Cipla Inc
Eli Lily and Company
Recent Developments in the Market:
In November 2023, Royalty Pharma plc and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., have revealed a collaboration aimed at expediting the clinical research program for Teva's olanzapine LAI (TEV-'749). This collaboration involves a funding agreement valued at USD 125 million to cover program costs. This funding arrangement allowed company to continue to advance the development of olanzapine LAI (TEV-'749), a vital initiative for Teva Pharmaceuticals, while preserving the company's resources for more advanced and futuristic formulations.
In October 2023, Coya Therapeutics, Inc., and Dr. Reddy's Laboratories formed an exclusive collaboration to develop and commercialize COYA 302, an investigational combination therapy for ALS.
In April 2023, CHEPLAPHARM announced that it had reached an agreement with Eli Lilly and Company to acquire the worldwide commercial rights to Zyprexa. The deal concerns the well-established and well-positioned olanzapine/olanzapine pamoate monohydrate ("OPM") portfolio, which includes ZypAdhera / Relprevv (depot IM [2]), Zyprexa IM2 (IM), Zyprexa Zydis / Zyprexa Velotab (ODT form), and Zyprexa (oral form, tablets). This acquisition strengthens the company's portfolio in the therapeutic field of the central nervous system and marks another milestone in CHEPLAPHARM's success story.
Global Olanzapine Market Report Scope:
Historical Data - 2020 - 2021
Base Year for Estimation - 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Application, Route of Administration, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application:
Schizophrenia
Bipolar Disorder
Others
By Route of Administration:
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa